Key Takeaways

Hoya Vision Care and The Hong Kong Polytechnic University announced clinical trial results showing that a new spectacle lens design for myopia control was able to halt clinically relevant myopia progression in 9 out of 10 children during the first year of wear, marking what the companies describe as the highest efficacy reported to date for Defocus Incorporated Multiple Segments (DIMS) Technology-based spectacle lenses.

The findings were presented at the ARVO 2026 annual meeting in Denver and stem from a randomized controlled clinical trial involving 196 myopic schoolchildren in Hong Kong between the ages of 4 and 12. According to the study, children wearing MiYOSMART iQ spectacle lenses demonstrated no average myopia progression over a 12-month period.

Researchers also reported that axial elongation remained below or comparable to levels seen in emmetropic children, or those without refractive errors.

The study represents the first time DIMS Technology-based spectacle lenses have demonstrated myopia control efficacy in children as young as 4 years old.

“At Hoya Vision Care, we imagine a world without myopia. This milestone is truly a generational leap in myopia control and represents an important step toward the vision we are committed to shaping for children around the world,” said John Goltermann Lassen, CEO of Hoya Vision Care. “Until today, no trial conducted on a myopia control spectacle lens has shown this level of effectiveness in controlling the condition.”

The trial found that children aged 4-12 wearing MiYOSMART iQ lenses experienced an average spherical equivalent refractive error (SER) change of +0.046 diopters over 12 months, compared with –0.534 diopters in children wearing standard single-vision lenses. Researchers said this corresponded to myopia control efficacy exceeding 100%.

Axial length changes were similarly favorable, with children wearing MiYOSMART iQ showing average axial elongation of just 0.075 mm compared with 0.346 mm in the single-vision control group. Notably, children aged 4-6 demonstrated 65% efficacy in SER control and 44% efficacy in axial length control over the 12-month period.

“Beyond stopping myopia progression on average over a period of 12 months and across childhood stages, these findings demonstrate—for the first time with myopia control spectacle lenses—efficacy in children from 4 years of age with early-onset myopia,” said Dr. Natalia Vlasak, global head of medical and scientific affairs at Hoya Vision Care. “This enables us to control it at a critical time when it is progressing rapidly and the risk of long-term impact is highest.”

For children aged 7-12, MiYOSMART iQ achieved more than 100% efficacy in SER control and 94% efficacy in axial length reduction compared with standard lenses, according to the study. Researchers also reported high compliance among participants for daily all-day lens wear, which they said contributed to effective myopia management outcomes.

MiYOSMART iQ represents the latest evolution of Hoya’s MiYOSMART platform, which is supported by more than 100 peer-reviewed scientific publications. The new design incorporates what the company calls Triple Enhanced Design (TED), featuring defocus segments positioned closer to the center of the lens, increased defocus power and an expanded treatment zone intended to improve peripheral retinal coverage.